Relief by Botulinum Toxin of Lower Urinary Tract Symptoms Owing to Benign Prostatic Hyperplasia: Early and Long-Term Results

Urology

Volumn 73, Issue 1, 2009, Pages 90-94

  Brisinda, Giuseppe ^a   Cadeddu, Federica ^b   Vanella, Serafino ^a   Mazzeo, Pasquale ^a   Marniga, Gaia ^a   Maria, Giorgio ^a  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^b TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CLINICAL EVALUATION; CLINICAL FEATURE; CONTROLLED STUDY; ECHOGRAPHY; FOLLOW UP; HUMAN; LONG TERM CARE; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RESIDUAL URINE; RESIDUAL VOLUME; TREATMENT OUTCOME; URINE FLOW RATE;

AGED; AGED, 80 AND OVER; BOTULINUM TOXIN TYPE A; HUMANS; INJECTIONS, INTRALESIONAL; MALE; MIDDLE AGED; NEUROMUSCULAR AGENTS; PROSTATIC HYPERPLASIA; PROSTATISM; TIME FACTORS;

EID: 57849094424     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2008.08.475     Document Type: Article

References (27)

1. Roehrborn C.G., Bartsch G., Kirby R., et al. Guidelines for the diagnosis and treatment of benign prostatic hyperplasia: a comparative, international overview. Urology 58 5 (2001) 642-650
2. Barry M.J., and Roehrborn C.G. Benign prostatic hyperplasia. BMJ 323 (2001) 1042-1046
3. de la Rosette J.J., Alivizatos G., Madersbacher S., et al. EAU guidelines on benign prostatic hyperplasia (BPH). Eur Urol 40 3 (2001) 256-263
4. Lu-Yao G.L., Barry M.J., Chang C.H., et al. Transurethral resection of the prostate among Medicare beneficiaries in the United States: time trends and outcomes. Urology 44 5 (1994) 692-698
5. Boyle P., Robertson C., Manski R., et al. Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia. Urology 58 5 (2001) 717-722
6. Narayan P., and Lepor H. Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia. Urology 57 3 (2001) 466-470
7. Maria G., Destito A., Lacquaniti S., et al. Relief by botulinum toxin of voiding dysfunction due to prostatitis. Lancet 352 9128 (1998) 625
8. Zermann D., Ishigooka M., Schubert J., et al. Perisphincteric injection of botulinum toxin type a: a treatment option for patients with chronic prostatic pain?. Eur Urol 38 4 (2000) 393-399
9. Leippold T., Reitz A., and Schurch B. Botulinum toxin as a new therapy option for voiding disorders: current state of the art. Eur Urol 44 2 (2003) 165-174
10. Maria G., Brisinda G., Civello I.M., et al. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology 62 2 (2003) 259-264
11. Lin V.K. Botulinum toxin and cellular proliferation in the prostate. J Urol 175 3 part 1 (2006) 817
12. Doggweiler R., Zermann D.H., Ishigooka M., et al. Botox-induced prostatic involution. Prostate 37 1 (1998) 44-50
13. Chuang Y.C., Chiang P.H., Huang C.C., et al. Botulinum toxin type a improves benign prostatic hyperplasia symptoms in patients with small prostates. Urology 66 4 (2005) 775-779
14. Chuang Y.C., and Chancellor M.B. The application of botulinum toxin in the prostate. J Urol 176 6 part 1 (2006) 2375-2382
15. Choo M.S. Investigating botulinum toxin A on the functional properties of the prostate. Eur Urol 52 2 (2007) 324-325
16. Antunes A.A., Srougi M., Coelho R.F., et al. Botulinum toxin for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Nat Clin Pract Urol 4 3 (2007) 155-160
17. Karsenty G., Baazeem A., Elzayat E., et al. Injection of botulinum toxin type a in the urethral sphincter to treat lower urinary tract dysfunction: a review of indications, techniques and results. Can J Urol 13 2 (2006) 3027-3033
18. Silva J., Silva C., Saraiva L., et al. Intraprostatic botulinum toxin type a injection in patients unfit for surgery presenting with refractory urinary retention and benign prostatic enlargement: effect on prostate volume and micturition resumption. Eur Urol 53 1 (2008) 153-159
19. Chuang Y.C., Giannantoni A., and Chancellor M.B. The potential and promise of using botulinum toxin in the prostate gland. Br J Urol Int 98 1 (2006) 28-32
20. Chuang Y.C., Huang C.C., Kang H.Y., et al. Novel action of botulinum toxin on the stromal and epithelial components of the prostate gland. J Urol 175 3 part 1 (2006) 1158-1163
21. Gkonos P.J., Krongrad A., and Roos B.A. Neuroendocrine peptides in the prostate. Urol Res 23 2 (1995) 81-87
22. McConnell J.D., Roehrborn C.G., Bautista O.M., et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349 25 (2003) 2387-2398
23. Witte L.P., Chapple C.R., de la Rosette J.J., et al. Cholinergic innervation and muscarinic receptors in the human prostate. Eur Urol 54 2 (2008) 326-334
24. Farnsworth W.E. Prostate stroma: physiology. Prostate 38 1 (1999) 60-72
25. Ruggieri M.R., Colton M.D., Wang P., et al. Human prostate muscarinic receptor subtypes. J Pharmacol Exp Ther 274 2 (1995) 976-982
26. Thompson I.M., Goodman P.J., Tangen C.M., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 349 3 (2003) 215-224
27. Chuang Y.C., Tu C.H., Huang C.C., et al. Intraprostatic injection of botulinum toxin type-A relieves bladder outlet obstruction in human and induces prostate apoptosis in dogs. BMC Urol 6 (2006) 12